AngioDynamics (NASDAQ:ANGO) Raised to Buy at Wall Street Zen

AngioDynamics (NASDAQ:ANGO) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Several other brokerages have also recently weighed in on ANGO. Canaccord Genuity Group increased their target price on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. HC Wainwright raised their price target on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Zacks Research lowered shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a report on Thursday, July 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, AngioDynamics currently has a consensus rating of “Hold” and an average target price of $19.50.

AngioDynamics Price Performance

Shares of ANGO stock opened at $15.75 on Friday. The business has a 50-day moving average price of $13.96 and a two-hundred day moving average price of $12.07. The firm has a market cap of $650.95 million, a P/E ratio of -18.10 and a beta of 0.33. AngioDynamics has a 12-month low of $9.06 and a 12-month high of $16.29.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The business had revenue of $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, research analysts expect that AngioDynamics will post -0.25 EPS for the current fiscal year.

Insider Buying and Selling

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the sale, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.00% of the stock is owned by insiders.

Hedge Funds Weigh In On AngioDynamics

Large investors have recently made changes to their positions in the business. Farther Finance Advisors LLC grew its stake in shares of AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 1,199 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in AngioDynamics during the 4th quarter valued at approximately $27,000. State of Wyoming purchased a new position in AngioDynamics during the second quarter valued at $31,000. Legal & General Group Plc purchased a new position in AngioDynamics during the second quarter valued at $45,000. Finally, Russell Investments Group Ltd. boosted its holdings in AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 3,213 shares in the last quarter. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.